What the FDA labels say about taking them together
Cyclosporine and perindopril
Perindopril's FDA label of March 13, 2024 names cyclosporine in its drug interactions section; cyclosporine's label does not name perindopril itself but warns about its class (ACE inhibitors). The perindopril label: “Use of potassium-sparing diuretics, potassium supplements or other drugs capable of increasing serum potassium can increase the risk of hyperkalemia.”
Check it at the source: the cyclosporine FDA label on DailyMed (effective August 10, 2026, Novartis Pharmaceuticals Corporation); the perindopril FDA label on DailyMed (effective March 13, 2024, Aurobindo Pharma Limited).
What does the cyclosporine label say about perindopril?
Cyclosporine's label does not name perindopril itself; it warns about its class (ACE inhibitors):
Cyclosporine label, drug interactionsCaution is also required when cyclosporine is coadministered with potassium sparing drugs (e.g., angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists), potassium-containing drugs as well as in patients on a potassium rich diet.
Source: FDA drug label (Neoral), Novartis Pharmaceuticals Corporation, effective August 10, 2026 (SPL set 94461af3-11f1-4670-95d4-2965b9538ae3), via openFDA; the full label on DailyMed
What does the perindopril label say about cyclosporine?
Perindopril label, drug interactionsUse of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia.
Source: FDA drug label (Perindopril Erbumine), Aurobindo Pharma Limited, effective March 13, 2024 (SPL set 87768fbf-7c63-47da-8925-0316f343d6ef), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Cyclosporine | Perindopril | |
|---|---|---|
| Labeled for | Organ transplant rejection, Rheumatoid arthritis | High blood pressure, Heart attack and coronary artery disease |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $1.04 per unit 0.05% eye emulsion | $0.495 per tablet 4 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once